What is Urologix?
Founded in 1991 and headquartered in Minneapolis, Urologix specializes in the development, manufacturing, and distribution of advanced medical products designed to alleviate symptoms associated with BPH. The company's core technological offerings include Cooled ThermoTherapy, which utilizes targeted microwave energy alongside a proprietary cooling mechanism to preserve healthy tissue, and the Prostiva RF Therapy System, which employs radio frequency energy to reduce urethral constriction. By focusing on patient-centric, minimally invasive interventions, Urologix maintains a critical role in the urology market, providing clinicians with effective alternatives to traditional surgical procedures.
How much funding has Urologix raised?
Urologix has raised a total of $139K across 1 funding round:
Debt
$139K
Debt (2021): $139K with participation from PPP
Key Investors in Urologix
PPP
Public-Private Partnership
What's next for Urologix?
With this late-stage financing, Urologix is well-positioned to accelerate its market penetration and refine its existing therapeutic platforms. The strategic allocation of this capital will likely focus on scaling distribution networks and enhancing the clinical adoption of its flagship therapy systems. As the demand for outpatient BPH treatments continues to rise, Urologix is poised to leverage its long-standing expertise to capture further market share, potentially exploring next-generation iterations of its microwave and radio frequency technologies to improve patient outcomes and operational efficiency for healthcare providers.
See full Urologix company page
